Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries.Its products are sold in approximately 125 countries. By Matthew Herper March 4, 2021. | © Lilly USA, LLC 2021. Eli Lilly and Company, Lilly USA, LLC and our wholly owned subsidiaries (collectively “Lilly”) are committed to help with individuals with disabilities participate in the workforce and ensure equal opportunity to compete for jobs. More than one in five people given a high dose of the drug, however, quit treatment in the trial, called SURPASS-1. Lilly Diabetes is committed to meeting the diverse needs of people with diabetes by offering a comprehensive and complementary portfolio of innovative solutions. Facebook Lilly Diabetes Journey Awards℠ is a service mark of Eli Lilly … The data could help Lilly's shot gain acceptance should it win approval. The Diabetes homepage for UK healthcare professionals provides options for asking questions on relevant Lilly products. Save job. Eli Lilly and Company is a major insulin manufacturer, located in Indianapolis, Indiana in the United States. Helps both the patient and healthcare provider make the most of their time together, and offers questions and topics for a patient to discuss and check off during the next interaction with his or her healthcare provider. Helps patients understand that they may reduce their risk for heart disease by managing their blood pressure, blood sugar, and cholesterol. Reprints. Emphasizes the importance of monitoring blood sugar as part of diabetes management. All rights reserved. Eli Lilly and Boehringer have taken the market-leading position with SGLT-2 drug Jardiance, and now the partners are changing their 2011 alliance agreement to focus on the med. Prof. Frank Snoek presents facts regarding psychological insulin resistance in people with type 2 diabetes and explores practical strategies to overcome it. This resource provides information on how gestational diabetes is diagnosed and managed. At any time should you choose to rescind your consent for future contact regarding the Lilly Diabetes Journey Awards Program or any other Lilly Diabetes initiative, please notify the Lilly Diabetes Journey Awards Administrators at 1-888-545-5115. Eli Lilly and Company, Lilly USA, LLC and our wholly owned subsidiaries (collectively “Lilly”) are committed to help with individuals with disabilities participate in the workforce and ensure equal opportunity to compete for jobs. Includes tips for lifestyle changes that may help. Connected care is an approach to diabetes management that uses digital tools and devices to inform patient and HCP decision-making. Eli Lilly's fourth-quarter profit jumped 41.5%, helped by higher demand for its diabetes drugs and a successful launch of its Covid-19 antibody treatment. Lilly unites caring with discovery to create medicines that make life better for people around the world. This resource also provides a step-by-step worksheet to help patients schedule their eye exams. Twitter Incretin hormones have an important role in the pathophysiology of obesity and type 2 diabetes, These videos show some of the primary organs involved in diabetes and explain their roles in glucose homeostasis in more detail, This series of videos educates on topics related to effective insulin therapy focused on the patient perspective using realistic case studies, How to enhance patient–healthcare provider interactions, An interactive case-based educational tool developed for healthcare professionals (HCPs) who work with adults who have type 2 diabetess. You are now leaving the LillyMedical.com Web site. This guide describes the signs of prediabetes, and how patients can reduce their risk of developing prediabetes. 3.1.16 03/2021 | GLOOTH00001 04/2015 Explains what patients should expect during a comprehensive eye exam. 3.1.16 03/2021 | GLOOTH00001 04/2015 Diabetes MSL Eli Lilly and Company Israel 2 hours ago Be among the first 25 applicants. These are focused resources for self-study. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. ... Basaglar ® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. The following resources have been developed to provide insights on a variety of topics for self-education and patient education. The company was founded in 1876 by, and named after, Col. Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. Facilitator Guide for the educational tool used for discussing hypoglycemia with patients. Emphasizes the importance of learning what low blood sugar is, symptoms of low blood sugar, how to help prevent low blood sugar before it starts, how to treat it, and what to do in an emergency. Topics include risks for and causes of hypoglycemia, classification levels, recommended treatment and tips for preventing and preparing for hypoglycemic events. Eli Lilly and Company, Lilly USA, LLC and our wholly owned subsidiaries (collectively “Lilly”) are committed to help with individuals with disabilities participate in the workforce and ensure equal opportunity to compete for jobs. This page includes links to Lilly sponsored clinical trials that have been published in peer reviewed journals over the last 3 years. This site is intended for US HealthCare Professionals only. Eli Lilly and Company: Innovation in Diabetes Care Eli Lilly and Company has success in produce and sells insulin in the United States in 1923 and in 1995 Eli Lilly has dominated the world insulin market with another company. Building on similar efforts Lilly has developed in lower-income communities in Mexico, India … INDIANAPOLIS, May 1, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Indiana University's Richard M. Fairbanks School of Public Health at IUPUI announced today the launch of a new neighborhood-based, data-driven pilot in Indianapolis to help address the high incidence of diabetes. Facebook This TIR Tip Sheet will help you use your own time-in-range to better manage your diabetes. | © Lilly USA, LLC 2021. In 1919, his heir Joseph Lilly hired biochemist George Henry Alexander Clowes as director of biochemical research. Eli Lilly's experimental diabetes injection tirzepatide outperformed Novo Nordisk's drug Ozempic in a Phase 3 study, showing greater reductions in blood sugar and weight loss, the company reported Thursday. Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study Published Date: May 22, 2019 Publication Link Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5) Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Save this job with your existing LinkedIn profile, or create a new one. Explains how diabetes may affect a patient’s kidneys and walks through tests that a healthcare provider may recommend to check kidney health. INDIANAPOLIS and CAMBRIDGE, Mass., April 4, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics today announced a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes. In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centers on compounds representing several of the largest diabetes treatment classes. Eli Lilly said its new drug, known as tirzepatide, significantly reduced both A1C blood sugar levels and body weight in patients with type 2 diabetes, … This resource explains how the kidneys work, signs and symptoms of kidney disease, tests for kidney health, and patient actions to help care for their kidneys. Facebook About Lilly Diabetes Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. All rights reserved. Adobe. Time in Range: A Measure of Glycemic Control, Working Together to Use Time in Ranges (TIRs) Data. About Lilly Diabetes Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. The list of publications below is limited to products that have been approved for use and may contain information about doses, uses, formulations and populations different from product labeling. | © Lilly USA, LLC 2021. About Lilly Diabetes Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. We encourage you to read the privacy policy of every Web site you visit.Click "Continue" to proceed or "Return" to return to LillyMedical.com. Sigilon is a privately-held biopharmaceutical company that is focused on discovering and developing "living therapeutics" with … Eli Lilly’s experimental diabetes drug reduced weight and blood sugar in clinical trial. Provides an overview of different complications—heart, eyes, feet, mouth, and kidneys—that are associated with diabetes. Please refer to the product’s Full Prescribing Information in the provided link. You are now leaving the LillyMedical.com Web site. This site is published by Eli Lilly and Company Ltd and is intended for Healthcare Professionals in the United Kingdom. Facebook All rights reserved. Explains how diabetes during pregnancy can cause problems for the patient and baby. Presentation of practical tools and skills that can be used to discuss hypoglycemia with people with diabetes that are on insulin therapy. If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979). Benefits and challenges should be discussed with patients to ensure success with the device. It also lists questions patients can ask their healthcare provider to help them stay on track. Lilly in Australia and New Zealand Learn More Please select the therapeutic area you would like to see more about. ... Req ID R-10667 Title Diabetes Access Associate City BOGOTA Country Colombia. Emphasizes the importance of learning what low blood sugar is in children, symptoms of low blood sugar displayed by children, how to help prevent low blood sugar before it starts, how to treat it, and what to do in an emergency. | © Lilly USA, LLC 2021. Lilly USA, LLC is not responsible for the privacy policy of any third-party Web sites. CGM-derived metrics can be used to assess glycemic control. Accommodation Needed to Submit Resume. If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979), LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose LevelsPublished Date: September 21, 2017Publication Link, Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100Published Date: August 2, 2019Publication LinkLilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 StudyPublished Date: May 22, 2019Publication LinkLilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)Published Date: January 2, 2019Publication LinkPatient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2Published Date: July 23, 2018Publication LinkSimilar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D SubpopulationPublished Date: May 31, 2018Publication LinkCharacteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trialsPublished Date: May 8, 2018Publication LinkSimilar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (Published Date: March 14, 2018Publication LinkClinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin GlarginePublished Date: March 30, 2017Publication Link, Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety studyPublished Date: April 23, 2020Publication Link, NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUEPublished Date: April 15, 2020Publication LinkNasal glucagon as a viable alternative for treating insulin‐induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover studyPublished Date: March 1, 2020Publication LinkA phase 3 multicenter, open‐label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school settingPublished Date: March 22, 2018Publication LinkProspective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world settingPublished Date: March 22, 2018Publication LinkEffects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trialPublished Date: November 19, 2017Publication LinkFaster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation StudyPublished Date: May 30, 2017Publication LinkGlucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 DiabetesPublished Date: February 16, 2016Publication LinkIntranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority StudyPublished Date: December 17, 2015Publication Link, Insulin exposure mitigates the increase of arterial stiffness in patients with type 2 diabetes and albuminuria: an exploratory analysisPublished Date: May 17, 2019Publication LinkFasting experience of patients with Type 2 diabetes mellitus on insulin therapy during Ramadan: VISION Ramadan substudyPublished Date: February 27, 2019Publication LinkPatterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa regionPublished Date: January 14, 2019Publication LinkRelative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized TrialPublished Date: March 24, 2018Publication LinkWhen basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitusPublished Date: December 15, 2017Publication LinkCREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continentsPublished Date: July 13, 2017Publication LinkSimulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic MedicationsPublished Date: July 3, 2017Publication LinkInsulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trialPublished Date: May 24, 2017Publication Link, Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID studyPublished Date: December 22, 2019Publication Link, Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover StudyPublished Date: May 29, 2020Publication LinkPharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled TrialPublished Date: May 29, 2020Publication LinkUltra Rapid Lispro Lowers Postprandial Glucose and More Closely Matches Normal Physiological Glucose Response Compared to Other Rapid Insulin Analogs: A Phase 1 Randomized, Crossover StudyPublished Date: May 21, 2020Publication LinkUltra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 diabetesPublished Date: December 9, 2019Publication Link, Ultra Rapid Lispro Improves Postprandial Glucose Control Compared With Lispro in Patients With Type 1 Diabetes: Results from the 26‐Week PRONTO‐T1D StudyPublished Date: June 15, 2020Publication LinkUltra Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Sub-StudyPublished Date: May 21, 2020Publication Link, No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with DulaglutidePublished Date: March 29, 2017Publication LinkOnce‐weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusionPublished Date: February 17, 2017Publication Link, Change in HbA1c Across the Baseline HbA1c Range in Type 2 DiabetesPatients Receiving Once-Weekly Dulaglutide Versus Other Incretin AgentsPublished Date: May 4, 2019Publication LinkEffect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programmePublished Date: March 30, 2018Publication LinkEffect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1cPublished Date: August 17, 2017Publication LinkNo calcitonin change in a person taking dulaglutide diagnosed with pre‐existing medullary thyroid cancerPublished Date: July 29, 2017Publication LinkAssessment of PancreasSafety in the Development Program of Once-Weekly GLP-1 Receptor Agonist DulaglutidePublished Date: March 10, 2017Publication Link, Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc AnalysisPublished Date: April 10, 2020Publication LinkOnce-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1cPublished Date: April 3, 2020Publication LinkEfficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1Published Date: March 26, 2020Publication LinkAchieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysisPublished Date: November 23, 2019Publication LinkEffect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trialPublished Date: July 31, 2019Publication LinkDulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialPublished Date: July 13, 2019Publication LinkEfficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)Published Date: June 21, 2019Publication LinkEfficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post‐hoc analyses of a randomized, double‐blind, phase III studyPublished Date: May 18, 2019Publication LinkChange in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin AgentsPublished Date: May 4, 2019Publication LinkWeight loss in patients with type 2 diabetes receiving once‐weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post‐hoc analysis of the AWARD‐4 study across baseline body mass index subgroupsPublished Date: March 15, 2019Publication LinkBody weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)Published Date: February 14, 2019Publication LinkGeneralizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United StatesPublished Date: February 3, 2019Publication LinkEfficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52‐week open‐label, randomized phase III trialPublished Date: August 21, 2018Publication LinkDulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trialPublished Date: June 14, 2018Publication LinkEffect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programmePublished Date: March 30, 2018Publication LinkDulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentrationPublished Date: March 23, 2018Publication LinkDulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trialPublished Date: February 23, 2018Publication LinkSubgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 DiabetesPublished Date: December 20, 2017Publication LinkEfficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetesPublished Date: September 14, 2017Publication LinkEffect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1cPublished Date: August 17, 2017Publication LinkNo calcitonin change in a person taking dulaglutide diagnosed with pre‐existing medullary thyroid cancerPublished Date: July 29, 2017Publication LinkEvaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studiesPublished Date: June 12, 2017Publication LinkDesign and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND ) trial on the cardiovascular effects of dulaglutidePublished Date: June 1, 2017Publication LinkPlacebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD ‐9)Published Date: April 10, 2017Publication LinkAnalysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in JapanPublished Date: March 29, 2017Publication LinkAssessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist DulaglutidePublished Date: March 10, 2017Publication LinkEfficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatmentPublished Date: March 7, 2017Publication Link, Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin AgentsPublished Date: May 4, 2019Publication LinkEffect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programmePublished Date: March 30, 2018Publication LinkDulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentrationPublished Date: March 23, 2018Publication LinkEffect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1cPublished Date: August 17, 2017Publication LinkPlacebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD ‐9)Published Date: April 10, 2017Publication Link. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. It aims to help patients understand their blood sugar goals, and how to use that information in self-management. Our strategic intent is to help more people with diabetes achieve their treatment goals and improve their outcomes and, as a result, become the market leading diabetes company in Taiwan. Your job seeking activity is only visible to you. This is an educational tool for discussing hypoglycemia with patients. Please select the therapeutic area you would like to see more about. Covers why it is important for diabetes patients to take good care of their kidneys. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them.
1 Zimmer-wohnung Konstanz Südkurier, Kawasaki Z1 1000, Iban Rechner Post, Oishii Preise Reutlingen, Bmw R75 Wehrmachtsgespann Kaufen, Heute In Herzogenaurach, Iptv Smarters Pro Zip, Blumenladen Heidelberg Handschuhsheim, Postfiliale Zb Karlsruhe Rüppurrer Str 87, Eduroam Cat Luxembourg, Tübinger Bücherfest 2020, Ferienhaus Auf Texel Mit Hund Und Eingezäuntem Garten,
